HDAC9 and ovarian carcinoma: MS-275, a HDAC inhibitor, inhibits the tumor spheroid formation of ovarian cancer cells and impacts on Talin‐1‐α5β1‐integrin‐mediated actin cytoskeleton and extracellular matrix protein remodeling 23.